Search Results - "Karsdal, M.A."

Call for standardized definitions of osteoarthritis and risk stratification for clinical trials and clinical use by Kraus, V.B, Blanco, F.J, Englund, M, Karsdal, M.A, Lohmander, L.S

“…Summary Osteoarthritis (OA) is a heterogeneous disorder. The goals of this review are (1) To stimulate use of standardized nomenclature for OA that could serve…”
Get full text

Disease-modifying treatments for osteoarthritis (DMOADs) of the knee and hip: lessons learned from failures and opportunities for the future by Karsdal, M.A, Michaelis, M, Ladel, C, Siebuhr, A.S, Bihlet, A.R, Andersen, J.R, Guehring, H, Christiansen, C, Bay-Jensen, A.C, Kraus, V.B

“…Summary Osteoarthritis (OA) is the biggest unmet medical need among the many musculoskeletal conditions and the most common form of arthritis. It is a major…”
Get full text

MAPKs are essential upstream signaling pathways in proteolytic cartilage degradation – divergence in pathways leading to aggrecanase and MMP-mediated articular cartilage degradation by Sondergaard, B.-C, Schultz, N, Madsen, S.H, Bay-Jensen, A.-C, Kassem, M, Karsdal, M.A

“…Summary Objectives Matrix metalloproteinases (MMPs) and aggrecanases are essential players in cartilage degradation. However, the signaling pathways that…”
Get full text

Osteoarthritis – a case for personalized health care? by Karsdal, M.A, Christiansen, C, Ladel, C, Henriksen, K, Kraus, V.B, Bay-Jensen, A.C

“…Summary For both economic and ethical reasons, identification of the optimal treatment for each individual patient is a pressing concern, not only for the…”
Get full text

Osteoarthritis year in review 2015: soluble biomarkers and the BIPED criteria by Bay-Jensen, A.C, Reker, D, Kjelgaard-Petersen, C.F, Mobasheri, A, Karsdal, M.A, Ladel, C, Henrotin, Y, Thudium, C.S

“…Summary Objective To review and summarize biomarker data published from April 2014 to May 2015 to provide insight to the ongoing work in the field of…”
Get full text

Treatment of symptomatic knee osteoarthritis with oral salmon calcitonin: results from two phase 3 trials by Karsdal, M.A, Byrjalsen, I, Alexandersen, P, Bihlet, A, Andersen, J.R, Riis, B.J, Bay-Jensen, A.C, Christiansen, C

“…Summary Purpose To evaluate the structure-modifying and symptom efficacy, as well as safety and tolerability of oral salmon calcitonin (sCT) formulated with a…”
Get full text

Identification and characterisation of osteoarthritis patients with inflammation derived tissue turnover by Siebuhr, A.S, Petersen, K.K, Arendt-Nielsen, L, Egsgaard, L.L, Eskehave, T, Christiansen, C, Simonsen, O, Hoeck, H.C, Karsdal, M.A, Bay-Jensen, A.C

“…Summary Objectives Osteoarthritis (OA) is a degenerative disease with a subset of patients experiencing joint inflammation, but C-reactive protein (CRP) has…”
Get full text

KBP-066A, a long-acting dual amylin and calcitonin receptor agonist, induces weight loss and improves glycemic control in obese and diabetic rats by Andreassen, K.V., Larsen, A.T., Sonne, N., Mohamed, K.E., Karsdal, M.A., Henriksen, K.

“…Dual amylin and calcitonin receptor agonists (DACRAs) are novel therapeutic agents that not only improve insulin sensitivity but also work as an adjunct to…”
Get full text

Calcitonin impairs the anabolic effect of PTH in young rats and stimulates expression of sclerostin by osteocytes by Gooi, J.H, Pompolo, S, Karsdal, M.A, Kulkarni, N.H, Kalajzic, I, McAhren, S.H.M, Han, B, Onyia, J.E, Ho, P.W.M, Gillespie, M.T, Walsh, N.C, Chia, L.Y, Quinn, J.M.W, Martin, T.J, Sims, N.A

“…Abstract The therapeutic goal of increasing bone mass by co-treatment of parathyroid hormone (PTH) and an osteoclast inhibitor has been complicated by the…”
Get full text

Serologically assessed extracellular matrix remodeling is affected by bariatric surgery in morbidly obese NAFLD patients with 12 months follow-up by Nielsen, M.J, Cabré, N, Karsdal, M.A, Leeming, D.J, Joven, J

Get full text

OA phenotypes, rather than disease stage, drive structural progression – identification of structural progressors from 2 phase III randomized clinical studies with symptomatic knee OA by Karsdal, M.A, Bihlet, A, Byrjalsen, I, Alexandersen, P, Ladel, C, Michaels, M, Andersen, J.R, Riis, B.J, Kraus, V, Bay-Jensen, A.C, Christiansen, C

“…Summary Background/Purpose The aim of this study was to identify key characteristics of disease progression through investigation of the association of…”
Get full text

Increased urinary excretion of C-telopeptides of type II collagen (CTX-II) predicts cartilage loss over 21 months by MRI by Dam, E.B., Ph.D, Byrjalsen, I., D.M.S.C, Karsdal, M.A., Ph.D, Qvist, P., Ph.D, Christiansen, C., Ph.D., D.M.S.C

“…Summary Objective Osteoarthritis (OA) is characterized by increased bone and cartilage metabolism leading to joint damage. The urinary excretion of…”
Get full text

Estimation of serum “true collagen type III formation” (Pro-C3) levels as a marker of non-alcoholic steatohepatitis in a prospective cohort by Leeming, D.J, Grove, J.I, Kaye, P, Hoad, C, Francis, S, Nielsen, M.J, Karsdal, M.A, Guha, I.N, Aithal, G.P

Get full text

Should subchondral bone turnover be targeted when treating osteoarthritis? by Karsdal, M.A., M.Sc., Ph.D, Leeming, D.J., M.Sc, Dam, E.B., M.Sc., Ph.D, Henriksen, K., M.Sc., Ph.D, Alexandersen, P., M.Sc., Ph.D, Pastoureau, P., Ph.D, Altman, R.D., M.D, Christiansen, C., M.D

“…Summary Objective Osteoarthritis (OA) is the most common form of arthritic disease, and it is a major cause of disability and impaired quality of life in the…”
Get full text

Serum Pro-C3 combined with clinical parameters is superior to established serological fibrosis tests at identifying patients with advanced fibrosis among patients with non-alcoholic fatty liver disease by Daniels, S.J, Nielsen, M.J, Krag, A, Eslam, M, Karsdal, M.A, Leeming, D.J, George, J

Get full text

Identification of serological biomarker profiles associated with total joint replacement in osteoarthritis patients by Arends, R.H.G.P, Karsdal, M.A, Verburg, K.M, West, C.R, Bay-Jensen, A.C, Keller, D.S

“…Summary Objective Establish a biomarker panel associated with all-cause total joint replacement (TJR) through identification of patients with osteoarthritis…”
Get full text

Characterization of the matrix driven osteoclast subtype in osteoarthritis by Thudium, C.S, Karsdal, M.A, Henriksen, K

Get full text

The effect of small molecule anti-inflammatory inhibitors on cartilage degradation is dependent on specific cytokine pathways by Thudium, C.S, Kjelgaard-Petersen, C.F, Mobasheri, A, Karsdal, M.A, Bay-Jensen, A.-C

Get full text

The effect of oral salmon calcitonin delivered with 5-CNAC on bone and cartilage degradation in osteoarthritic patients: a 14-day randomized study by Karsdal, M.A, Byrjalsen, I, Henriksen, K, Riis, B.J, Lau, E.M, Arnold, M, Christiansen, C

“…Summary Background The aim of this study was to investigate the pharmacokinetic and pharmacodynamic parameters of oral salmon calcitonin (oSCT) administered…”
Get full text

True Collagen Type III Formation (Pro-C3) is Predictive of Outcome in HCV Patients with Advanced Liver Fibrosis with in the Trent Study by Leeming, D.J, Dolman, G, Nielsen, M.J, Karsdal, M.A, Patel, K, Irving, W, Guha, I.N

Get full text